Rx Stocks Treading Water, But Cardinal Takes A Bath As Third Quarter Begins
Executive Summary
Cardinal Health's 25% plunge to begin the third quarter is an ominous sign for the pharmaceutical sector heading into the second half of the year
You may also be interested in...
Vioxx Shock Is Latest Headache For Rx Stocks; Is Election Day A Cure?
Pfizer's $27 bil. devaluation during the third quarter is strong evidence that Wall Street's aversion to drug stocks goes far beyond the Vioxx withdrawal
Vioxx Shock Is Latest Headache For Rx Stocks; Is Election Day A Cure?
Pfizer's $27 bil. devaluation during the third quarter is strong evidence that Wall Street's aversion to drug stocks goes far beyond the Vioxx withdrawal
Cardinal Fee-For-Service Distribution Transition Slows Earnings Growth
Cardinal's slower-than-expected conversion of its contracts to the fee-for-service distribution model has contributed to a slowdown in earnings growth